Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF

被引:0
作者
M Offidani
L Corvatta
A Olivieri
S Rupoli
J Frayfer
A Mele
E Manso
M Montanari
R Centurioni
P Leoni
机构
[1] Ancona University School of Medicine,Department of Hematology
[2] Torrette Hospital,Department of Microbiology
来源
Bone Marrow Transplantation | 1999年 / 24卷
关键词
infections; peripheral blood progenitor cell transplantation; mucositis; neutropenia; antimicrobial prophylaxis;
D O I
暂无
中图分类号
学科分类号
摘要
Infectious complications after autologous peripheral blood progenitor cell transplantation (PBPCT) have been reported in a few studies including small patient numbers. The present study was performed to assess the incidence, types, outcome and factors affecting early and late infections in 150 patients aged 18 to 68 years (median 46.5) who underwent high-dose therapy, with G-CSF. Patients were kept in reverse isolation rooms and received antimicrobial chemoprophylaxis with oral quinolone and fluconazole. One hundred and fifteen patients (76.7%) developed fever (median 3 days, range 1–29); 20 patients (55.5%) had Gram-positive and 13 (36.2%) Gram-negative bacterial infections. There were no fungal infections or infection-related deaths. Mucositis grade II–IV (P = 0.0001; odds ratio 3.4) and >5 days on ANC<100/μl (P = 0.0001; odds ratio 2.3) correlated with development of infection. Only days with ANC <100/μl affected infection outcome (P = 0.0024) whereas the antibiotic regimen did not. After day +30 there were four cases of bacterial pneumonitis (2.7%), one case of fatal CMV pneumonia (0.8%) and 20 of localized VZV infection (13.3%). Reduction of neutropenia duration with PBPCT and G-CSF is not enough to prevent early infectious complications since only a few days of severe neutropenia and mucositis are related to development of early infections. However, no infection-related deaths were seen. Although Gram-positive organisms were the major cause of bacteremia, a glycopeptide in the empirical antibiotic regimen did not affect infection outcome. In PBPCT recipients, early and late opportunistic infections were notably absent, which was at variance with what was seen with bone marrow recipients. Efforts should be made to prevent mucositis and neutropenia and identify new strategies of antibacterial prophylaxis.
引用
收藏
页码:1079 / 1087
页数:8
相关论文
共 50 条
  • [41] Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation
    Bolwell, B
    Vredenburgh, J
    Overmoyer, B
    Gilbert, C
    Chap, L
    Menchaca, DM
    Cruickshank, S
    Glaspy, J
    BONE MARROW TRANSPLANTATION, 2000, 26 (02) : 141 - 145
  • [42] High-dose chemotherapy with peripheral blood progenitor cell transplantation in the adjuvant treatment of breast cancer
    Rodenhuis, S
    Huitema, ADR
    van Dam, FSAM
    de Vries, EGE
    Beijnen, JH
    CANCER JOURNAL, 2000, 6 : S125 - S130
  • [43] Sequential high-dose treatment with peripheral blood progenitor cell transplantation in patients with multiple myeloma
    Goldschmidt, H
    Hegenbart, U
    Moos, M
    Eugenhart, R
    Wannenmacher, M
    Haas, R
    Hunstein, W
    STEM CELLS, 1995, 13 : 36 - 41
  • [44] Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients
    Martino, Massimo
    Pratio, Giulia
    Messina, Giuseppe
    Irrera, Giuseppe
    Massara, Elisabetta
    Messina, Giuseppe
    Console, Giuseppe
    Iacopino, Pasquale
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 77 (05) : 410 - 415
  • [45] M-CSF improves protection against bacterial and fungal infections after hematopoietic stem/progenitor cell transplantation
    Kandalla, Prashanth K.
    Sarrazin, Sandrine
    Molawi, Kaaweh
    Berruyer, Carole
    Redelberger, David
    Favel, Anne
    Bordi, Christophe
    de Bentzmann, Sophie
    Sieweke, Michael H.
    JOURNAL OF EXPERIMENTAL MEDICINE, 2016, 213 (11) : 2269 - 2279
  • [46] Successful autologous peripheral blood stem cell transplantation with rituximab administration for pediatric diffuse large B-cell lymphoma
    Imamura, T
    Yoshihara, T
    Morimoto, A
    Ishida, H
    Sugimoto, T
    Imashuku, S
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2006, 23 (01) : 19 - 24
  • [47] The combination of erythropoietin and granulocyte colony-stimulating factor increases the rate of haemopoietic recovery with clinical benefit after peripheral blood progenitor cell transplantation
    Pierelli, L
    Scambia, G
    Menichella, G
    DOnofrio, G
    Salerno, G
    Panici, PB
    Foddai, ML
    Vittori, R
    Lai, M
    Ciarli, M
    Puglia, G
    Mancuso, S
    Bizzi, B
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 92 (02) : 287 - 294
  • [48] Infectious complications after post-transplantation cyclophosphamide and anti-thymocyte globulin-based haploidentical stem cell transplantation
    Mohty, Razan
    Brissot, Eolia
    Battipaglia, Giorgia
    Ruggeri, Annalisa
    Dulery, Remy
    Bonnin, Agnes
    Mediavilla, Clemence
    Sestili, Simona
    Belhocine, Ramdane
    Vekhoff, Anne
    Ledraa, Tounes
    Lapusan, Camelia Simona
    Adaeva, Rosa
    Isnard, Francoise
    Legrand, Olivier
    Mohty, Mohamad
    Malard, Florent
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 187 (03) : E64 - E68
  • [49] Surveillance of nosocomial infections in adult recipients of allogeneic and autologous bone marrow and peripheral blood stem-cell transplantation
    Dettenkofer, M
    Ebner, W
    Bertz, H
    Babikir, R
    Finke, J
    Frank, U
    Rüden, H
    Daschner, FD
    BONE MARROW TRANSPLANTATION, 2003, 31 (09) : 795 - 801
  • [50] Surveillance of nosocomial infections in adult recipients of allogeneic and autologous bone marrow and peripheral blood stem-cell transplantation
    M Dettenkofer
    W Ebner
    H Bertz
    R Babikir
    J Finke
    U Frank
    H Rüden
    F D Daschner
    Bone Marrow Transplantation, 2003, 31 : 795 - 801